SCHEMBL6071629

SCHEMBL6071629

c1ccc(N2CCc3ccccc32)nc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 2/20 0.62
GRIN1 Q05586 2/20 0.56
GRIN2B Q13224 2/20 0.56
GRIN2D O15399 1/20 0.56
GRIN3B O60391 1/20 0.56
GRIN2A Q12879 1/20 0.56
GRIN2C Q14957 1/20 0.56
GRIN3A Q8TCU5 1/20 0.56
CRBN Q96SW2 1/20 0.53
ALDH1A1 P00352 3/20 0.49
MAPT P10636 1/20 0.49
LMNA P02545 2/20 0.47
TP53 P04637 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPK8 P45983 1/20 0.47
MAPK9 P45984 1/20 0.47
NPC1 O15118 1/20 0.47
HPGD P15428 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29721478 1.00 ROCK1 (0.62) ROCK1GRIN1GRIN2BGRIN2DGRIN3B
SCHEMBL18012073 0.90 ROCK1 (0.64) ROCK1GRIN1GRIN2BGRIN2DGRIN3B
SCHEMBL29721693 0.81 ROCK1 (0.61) ROCK1ALDH1A1MAPTLMNATP53
SCHEMBL3239758 0.81 ROCK1 (0.61) ROCK1ALDH1A1MAPTLMNATP53
SCHEMBL9379977 0.81 ROCK1 (0.61) ROCK1ALDH1A1MAPTLMNATP53
SCHEMBL17335801 0.81 ROCK1 (0.57) ROCK1GRIN1GRIN2BGRIN2DGRIN3B
SCHEMBL28518109 0.81 GRIN2D (0.49) ROCK1GRIN1GRIN2BGRIN2DGRIN3B
SCHEMBL29721709 0.81 ROCK1 (0.49) ROCK1GRIN1GRIN2BGRIN2DGRIN3B
SCHEMBL29721714 0.81 ROCK1 (0.63) ROCK1GRIN1GRIN2BGRIN2DGRIN3B
SCHEMBL29721770 0.81 ROCK1 (0.63) ROCK1GRIN1GRIN2BGRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108947896-B Synthetic method of alpha-aryl-alpha- (5-pyridyl) acetate derivative 华南理工大学 2021-09-21 CN disclosed
US-20060241149-A1 Chemical compounds ADAMS JERRY L 2006-10-26 US disclosed
EP-1581514-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-10-05 EP disclosed
WO-2004043379-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-05-27 WO disclosed
EP-1349535-A2 INDOLE/INDOLINE BASED HYBRID DYES AND INDOLE/INDOLINE BASED HYBRID DYE INTERMEDIATE PRODUCTS Henkel Kommanditgesellschaft auf Aktien (DE) 2003-10-08 EP disclosed
WO-2002055609-A2 INDOLE/INDOLINE BASED HYBRID DYES AND INDOLE/INDOLINE BASED HYBRID DYE INTERMEDIATE PRODUCTS HENKEL KGAA (DE) 2002-07-18 WO disclosed
WO-2000006575-A2 AZABICYCLIC COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241149-A1 Chemical compounds CHKB, MAP3K20, MAP3K6 ROCK1 739/4885GRIN1 3082/4885GRIN2B 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.